BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

901 related articles for article (PubMed ID: 31038663)

  • 1. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
    Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
    Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
    Dudnik E; Peled N; Nechushtan H; Wollner M; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadari N; Urban D; Mishaeli M; Zer A; Allen AM; Rabinovich NM; Rotem O; Kuznetsov T; Shochat T; Roisman LC; Bar J;
    J Thorac Oncol; 2018 Aug; 13(8):1128-1137. PubMed ID: 29723688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
    JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.